Table 3. Clinical features of the patients enrolled in this study.

Patient	Sex (M/F)	Age (years old)	Side of tumor	Date of surgery (year, month)	Histological diagnosis (WHO classification)	Months of survival	Preoperative KPS	Postoperative KPS	Preoperative Deficit	Postoperative Deficit (at the discarge)	Postoperative treatment	Recurrence
1	M	77	Right fronto-pariel	2011, Sept.	IV grade	6	70	70	Moderate left hemiparesis	No further deficit than preop time	CT + RT (Stupp protocol*), Levetiracetam	After 6 months
2	M	75	Right fronto-temporal	2013, Sept.	IV grade	11	80	80	Mild ideo-motor apraxia, mild left lower limb deficit with some difficulties with walking	No further deficit than preop time	CT + RT (Stupp protocol*), Levetiracetam	After 10 months
3	F	72	Right fronto-temporal	2013, Sept.	IV grade	11	80	90	Mild ideo-motor slowing, mild motor deficit in left upper limb	Improvement of ideo-motor slowing and preop motor deficit	CT + RT (Stupp protocol*), Levetiracetam	No
4	M	36	Left Temporal	2013, Sept.	III grade	Living	100	100	No deficit	No deficit	RT	No
5	F	45	Left frontal	2013, Oct.	II grade	Living	90	90	Dysphasia	Improvement of preoperative dysphasia	RT after the first operation. CT after the second operation. Levetiracetam	After 22 month (Re-operation)
6	F	48	Left frontal	2013, Dec.	II grade	Living	90	100	Dysphasia	Improvement of preoperative dysphasia	RT. Levetiracetam	No
7	F	65	Left fronto-temporal	2013, Nov.	IV grade	17	80	80	Right hemiparesis (Moderate in upper limb, mild in lower limb)	No further deficit than preop time	CT+ RT (Stupp protocol*). Levetiracetam	After 13 months
8	F	37	Right temporal	2014, Nov.	IV grade	Living	90	90	No deficit	No deficit	CT+ RT (Stupp protocol*). Levetiracetam	No
9	F	68	Left Temporo-parietal	2015, Oct.	IV grade	14	90	90	Mild ideo-motor slowing, very mild right upper limb deficit	No further deficit than preop time	RT + CT (Stupp protocol*). Levetiracetam	After 10 months
10	F	27	Left temporal	2016, Feb.	II grade	Living	100	100	Dysphasia	No deficit	RT + CT (Stupp protocol*). Levetiracetam	No

*Stupp protocol: Adjuvant treatment with radiotherapy (RT) and chemotherapy (CT). Focal radiotherapy was delivered once daily at 2Gy per fraction, 5 day/week, for a total of 60 Gy, as prescribed by the radiation oncologist, according to the guidelines of the International Commission on Radiological Units. Concomitant treatment with temozolomide was prescribed by the oncologist at a dose of 75 mg/m² for each day of radiation treatment. Four weeks after radiotherapy, patients received adjuvant temozolomide chemotherapy, 150 to 200 mg/m² on days 1 to 5 at 28-day intervals. All patients were subjected to radical exeresis, except patient #10 subjected to a subtotal exeresis.